Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for evidence in the transcript. The transcript is from Carpenter Technology's Q4 2021 earnings call. Management discusses various things: safety, financial results, end-use markets, Athens facility, hot strip mill, etc. They talk about demand recovery, backlog up 20% sequentially, bookings up 14%, lead times extending. They mention that they are seeing increasing signs of recovery. They talk about market share growth opportunities. They mention that they received another important qualification for Athens. They talk about the hot strip mill commissioning. But the key is: does management explicitly state that the size of individual orders, contracts, projects, etc., is escalating compared to their own past? They talk about backlog and bookings increasing, but that could be volume. They talk about lead times extending, which might indicate more demand but not necessarily larger individual orders. They mention that they are seeing demand conditions improve sequentially. They talk about "record shipments for heavy-duty truck applications" but that's volume. They also mention that they are "working closely with customers" and "strengthening key customer relationships." But nothing about the size of individual deals growing. They mention that Athens will be a competitive differentiator as industry build rates rise and lead times extend. That suggests they expect more business, but not necessarily larger individual orders. They talk about the hot strip mill enabling them to produce thinner strip for electrification, and they are already producing materials for new motors. But again, that's about capability, not about deal size escalation. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size." There is no mention of that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.